The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma

BACKGROUND: Mepolizumab and omalizumab are treatments for distinct but overlapping severe asthma phenotypes. OBJECTIVE: To assess if patients eligible for both biologics but not optimally controlled with omalizumab experience improved asthma control when switched directly to mepolizumab. METHODS: OS...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Allergy
Autors principals: Chapman, Kenneth R., Albers, Frank C., Chipps, Bradley, Muñoz, Xavier, Devouassoux, Gilles, Bergna, Miguel, Galkin, Dmitry, Azmi, Jay, Mouneimne, Dalal, Price, Robert G., Liu, Mark C.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2019
Matèries:
ORIGINAL ARTICLES
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6790683/
https://ncbi.nlm.nih.gov/pubmed/31049972
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/all.13850
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars